Compare Paychex, Inc. (PAYX) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paychex, Inc. vs Zimmer Biomet Holdings Inc — how do they compare? Paychex, Inc. trades at $114.78 (market cap $40.85B), while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $18.05B). The key difference: Paychex, Inc. is far larger — about 2.3× Zimmer Biomet Holdings Inc's market cap, and Paychex, Inc. pays the higher dividend (4.15%). Which is the better fit depends on your goals.
| PAYX | ZBH | |
|---|---|---|
Market Cap | $40.85B | $18.05B |
Sector | Industrials | Health |
52-Week High | $135.46 | $104.26 |
52-Week Low | $85.57 | $79.58 |
Enterprise Value | $44.33B | $25.11B |
Dividend Yield | 4.15% | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paychex (PAYX) trades at $116.93, down 3.93% in the last session. The stock shows strong profitability with a net income margin of 27.03% and ROE of 44.77%. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.32 surpassing the $1.31 estimate. Technical indicators are mixed, with a bearish moving average signal but RSI suggesting potential oversold conditions. The company continues to expand its AI-driven WISE platform, enhancing service efficiency for small businesses.
The outlook for PAYX is cautiously optimistic, supported by robust cash flow and strategic AI integration. However, risks include elevated valuation multiples and competitive pressures in the HR solutions space. Analyst consensus is a 'Hold' with a $120 price target, indicating limited near-term upside from current levels amid balanced growth and risk factors.
ZBH trades at $94.22, down 3.93% on the day, with a bearish technical signal but oversold RSI readings. Recent earnings beats and raised 2026 guidance support fundamentals, with revenue growth and strong gross margins. Leadership promotions aim to accelerate commercial transformation, while cash flow trends show operational strength.
The stock offers upside to the $104.88 consensus target, but faces headwinds from debt levels and competitive pressures. Near-term support at $92 is critical; a hold rating aligns with mixed analyst views. Earnings execution and procedure demand growth are key catalysts for valuation expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
